Big pharma has been up in arms for years over what it sees as India’s refusal to respect intellectual property rights (IPR), and the US has long accused the country - the world’s leading exporter of inexpensive generics - of being one of the worst “delinquents” in this area.
India’s IPR rules are now also coming under intense scrutiny in ongoing free trade talks with the European Free Trade...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?